| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 06 Nov 2026 | SCHEDULE 13G/A |
| 06 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
-- Presented additional 36-week results and 16-week off-drug findings from Part B of the SIGNAL-AA clinical trial of bempikibart in late-breaking oral and poster presentations at EADV Congress 2026; data supports further development of b... |
| 28 Oct 2026 | SCHEDULE 13G |
| 14 Oct 2026 |
Form 4: Morrison Jodie Pope, Director
Sold 3,221 shares ($26.8K) |
| 14 Oct 2026 |
Form 4: Violette Shelia M., Chief Scientific Officer
Sold 917 shares ($7.63K) |
| 14 Oct 2026 |
Form 4: Kalowski Lee, CFO and President
Sold 1,301 shares ($10.8K) |
| 09 Oct 2026 | SCHEDULE 13G |
| 30 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 |
| 14 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer |
| 27 Aug 2026 |
Form 4: Morrison Jodie Pope, Director
Sold 9,845 shares ($163K) |
| 27 Aug 2026 |
Form 4: Kalowski Lee, CFO and President
Sold 3,972 shares ($65.8K) |
| 27 Aug 2026 |
Form 4: Violette Shelia M., Chief Scientific Officer
Sold 2,798 shares ($46.3K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 05 Aug 2026 | 10-Q |
Loading...